Actualités Galapagos - GLPG | Actions Euronext

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a...

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities Galapagos intends to create a new...

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that...

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext...

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate...

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with...

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in...

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 New Phase 1/2 data support the potential of our CAR...

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster...

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update We are advancing our pipeline and accelerating innovation...

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the...

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos...

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos...

Galapagos receives transparency notification from EcoR1 Capital

Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ:...

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from EcoR1 Capital Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Galapagos (GLPG)

Outils de qualité professionnelle, pour des investisseurs individuels.

GLPG Actualités

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from EcoR1 Capital

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Galapagos (GLPG) Actualités

Galapagos (GLPG)

Outils de qualité professionnelle, pour des investisseurs individuels.

GLPG Actualités

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from EcoR1 Capital

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités